Key result
Compounds A3 and A4 (2-aryl-isoindolin-1-ones) exhibited broad and potent in vitro antiviral activity against multiple EV-A71 clinical isolates with EC50 values of 1.23–1.76 μM.
Why the study?
Enterovirus 71 is the main pathogen causing childhood hand, foot and mouth disease, but effective medicine is currently unavailable.
Novel 2-aryl-isoindolin-1-one compounds, particularly A3 and A4, demonstrate potent in vitro antiviral activity against Enterovirus A71, representing a promising scaffold for further drug development.
May support preclinical development of isoindolinones for EV-A71; leaves open clinical translation.
Enterovirus 71 (EV-A71) is the main causative pathogen of childhood hand, foot and mouth disease. Effective medicine is currently unavailable for the treatment of this viral disease. Using the fragment-hopping strategy, a series of 2-aryl-isoindolin-1-one compounds were designed, synthesized and investigated for their in vitro antiviral activity towards multiple EV-A71 clinical isolates (H, BrCr, Shenzhen98, Jiangsu52) in Vero cell culture in this study. The structure–activity relationship (SAR) studies identified 2-phenyl-isoindolin-1-ones as a new potent chemotype with potent antiviral activity against EV-A71. Ten out of the 24 tested compounds showed significant antiviral activity (EC50 < 10 µM) towards four EV-A71 strains. Compounds A3 and A4 exhibited broad and potent antiviral activity with the 50% effective concentration (EC50) values in the range of 1.23–1.76 μM. Moreover, the selectivity indices of A3 and A4 were significantly higher than those of the reference compound, pirodavir. The western blotting experiment indicated that the viral VP1 was significantly decreased at both the protein and RNA level in a dose-dependent manner following treatment with compound A3. Moreover, compound A3 inhibited the viral replication by acting on the virus entry stage. In summary, this study led to the discovery of 2-aryl-isoindolin-1-ones as a promising scaffold with potent anti-EV-A71 activities, which deserves further in-depth studies.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2019) studied Enterovirus 71 (EV-A71) infection. 2-aryl-isoindolin-1-ones (compounds A3 and A4) vs. pirodavir was evaluated on in vitro antiviral activity (EC50). Compounds A3 and A4 (2-aryl-isoindolin-1-ones) exhibited broad and potent in vitro antiviral activity against multiple EV-A71 clinical isolates with EC50 values of 1.23–1.76 μM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: